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Abstract
Introduction The aim of the study was to describe patterns of neuromuscular weakness using a
combination of electromyography and histology, and to evaluate functional outcome in patients
following complicated cardiovascular surgery.
Methods Fifteen adults requiring long-term mechanical ventilation (>15 days) following cardiovascular
surgery associated with postoperative complications were prospectively included. Electrophysiological
and histological analyses (muscle and nerve) were performed when failure to wean from mechanical
ventilation associated with peripheral neuromuscular weakness was noticed. Functional disability was
evaluated 12 months after surgery.
Results Six patients had a predominantly axonal neuropathy, six presented with myopathy, and three
patients had a combination of axonal neuropathy and myopathy. All of them presented with acute
tetraparesis and failure to wean from mechanical ventilation. All of the study patients who received
corticosteroids exhibited a myopathic pattern (with or without axonopathic changes) but never an
axonopathic pattern only. Only two of the eight survivors at 12 months were not ambulatory. These two
patients had no detectable compound muscle action potential on electrophysiological examination.
Conclusion The combination of electromyographic evaluation and neuromuscular histological
abnormalities could help to identify the type and severity of neuromuscular weakness, in turn helping
to evaluate the patient's potential functional prognosis.
Keywords: critical illness, electromyography, myopathy, muscle biopsy, polyneuropathy
Introduction
Critical illness polyneuropathy (CIP) and myopathy are neu-
romuscular disorders that occur in critically ill patients [1,2].
Clinical features often consist of difficulty in weaning from
mechanical ventilation, tetraparesis and muscle wasting of the
limbs, with tendon reflexes absent or markedly decreased.
Regarding the causes of these disorders, it has been hypoth-
esized that systemic inflammatory response syndrome (SIRS)
and sepsis, with their impact on the body's defence system,
may be involved [3,4]. Associations with drugs such as neu-
romuscular blocking agents, steroids and catecholamines
have also been suggested [3,5,6]. In addition, other factors
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such as malnutrition, underlying disease, immobility and antibi-
otics have been considered [7].
Patients with weakness acquired in the intensive care unit
(ICU) are often sedated and mechanically ventilated, and have
unreliable sensory and motor examinations, and so diagnosis
can be quite difficult because of the prolonged sedation. [8]
Electromyography is useful for identifying and localizing a
lesion to a particular component of the motor unit. Using elec-
tromyography, Bolton [9] and Zochodne [10] and their col-
leagues were the first to identify one of the major
neuromuscular causes of neuromuscular weakness in acute ill
patients, namely CIP [9,10]. However, use of electromyogra-
phy and clinical examination without obtaining neuromuscular
biopsy findings may lead to some patients being diagnosed as
having CIP only [2,11]. Therefore, such examinations may dis-
tract attention from other neuromuscular disorders that occur
in the critically ill, thus leading to identification of phenomena
of neuromuscular junction blockade or critical illness myopa-
thy, or a combined picture involving both syndromes.
Because of this, and because of the lack of studies evaluating
neuromuscular disorders in ICUs using a combination of his-
topathological (nerve and muscle) and electromyographic
studies, we conducted the present study in which we moni-
tored critically ill patients prospectively following complicated
cardiovascular surgery. After inclusion in the study, serial clin-
ical, neuromuscular biopsy and electromyographic analyses
were systematically conducted. Using this method we were
able to diagnose neuromuscular disorders; to identify the pre-
dominant neurogenic or myogenic pattern, or a combined pic-
ture involving both lesions; and to compare these findings with
functional outcome.
Methods
Hospital
This prospective study was carried out in the ICU of a teaching
hospital with an 11-bed surgical unit. Annually, 650 critically ill
patients are admitted following cardiac surgery using cardiop-
ulmonary bypass.
Patients
From 1998 to 2002, 15 patients who had a complicated
course (with one or more organ dysfunctions) following cardi-
ovascular surgery were prospectively included after prolonged
mechanical ventilation (>15 days) associated with tetrapare-
sis and failure to wean. Peripheral electromyographic analysis
and neuromuscular biopsy were performed in all of these
patients to determine the cause of limb weakness and dia-
phragm dysfunction. The medical committee of the hospital
approved the study, and informed consent was obtained from
the relatives of the patients.
Excluded were those patients who were suspected of having
pre-existing polyneuropathy because they had a diagnosis of
chronic diabetes mellitus, alcohol abuse, HIV infection, or end-
stage renal disease (associated with chronic haemodialysis),
or had used neurotoxic medication. Patients with acute or
chronic spinal cord lesion, myasthenia gravis, or Guillain–
Barré syndrome were also excluded.
After the patients had been enrolled, clinical examination was
performed daily during their stay in the ICU, and we assessed
motor deficit, muscle wasting, sensory loss and tendon
reflexes.
In these patients undergoing cardiac surgery, at ICU admis-
sion the Euroscore was caculated to evaluate risk for postop-
erative mortality [12]. This prognostic scoring system was
developed in Europe for use in patients undergoing cardiac
surgery. The score is calculated by simple arithmetic (additive
model) using risk factors that were found to be robust in pre-
dicting postoperative mortality, such as age, sex, emergency
surgery, preoperative left ventricular dysfunction and type of
surgery. Organ failure score and presence of SIRS were
noted, according to criteria presented by Bone and coworkers
[13], at admission and during the clinical course [7]. The diag-
nosis of SIRS required the presence of two or more of the fol-
lowing criteria [13]: body temperature >38°C or <36°C; heart
rate >90 beats/min; tachypnoea >20 breaths/min; and hyper-
ventilation, as indicated by an arterial carbon dioxide tension
<32 mmHg, leucocyte count >12 g/l or <4 g/l, or presence of
>10% immature neutrophils.
Use and dosage of neuromuscular blocking agents and intra-
venous corticosteroids were registered daily.
Electrophysiological monitoring and neuromuscular biopsies
were performed as soon as the neuromuscular disorder was
recognized after the end of prolonged sedation associated
with mechanical ventilation (>15 days after the onset of
mechanical ventilation). Failure to wean from mechanical ven-
tilation was characterized by inability to extubate or inefficient
spontaneous ventilation through tracheostomy. Peripheral
weakness affected both proximal and distal muscle groups
and was defined as failure to move against gravity.
Electromyography
Nerve conduction studies were performed with Nicolet Viking
IV apparatus via percutaneous stimulation and surface record-
ing. Quantitative concentric needle electromyography was
performed in distal and proximal muscles of upper extremities
(such as deltoid, muscle interosseus I, and muscle abductor
pollicis brevis) and lower extremities (such as tibialis anterior
and flexor hallucis brevis). Electroneurography included upper
(median or ulnar) nerves and lower (peroneal or sural) nerves.
In patients who could not exercise, repetitive stimulation at
20–30 Hz was also given. Diaphragmatic and phrenic nerve
studies were not performed.Available online http://ccforum.com/content/8/6/R358
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Electromyography reports were analyzed by the same doctor
and categorized as axonal polyneuropathy or myopathy, or a
combination thereof. Patients were diagnosed as having
axonal sensorimotor polyneuropathy if electrodiagnostic stud-
ies revealed very low amplitude or absent sensory responses
and low motor amplitudes with normal or mildly reduced con-
duction velocities. Patients were diagnosed as having myopa-
thy in the setting of low or normal motor amplitudes, with
relatively normal sensory responses. Short duration of motor
unit potentials with normal or early recruitment with or without
fibrillation potentials, or fibrillation potentials and either no fir-
ing or polyphasic motor unit potentials of normal duration were
also considered to reflect myopathy.
Combined muscle and nerve biopsies
Muscular biopsies were obtained in all 15 patients, from skel-
etal muscle specimens of the vastus lateralis or anterior tibialis
muscles, under local anaesthesia (lidocaine 1% 100–150 mg)
if necessary; these patients did not have thombocytopenia or
coagulopathy. Muscle samples were first snap frozen in iso-
pentane precooled in liquid nitrogen and stored at -80°C until
examination. For routine histology, the samples were placed in
formaldehyde fixative and paraffin embedded. For conven-
tional transmission electron microscopy, specimens were fixed
in 2.5% glutaralehyde in 0.1 mol/l phosphate-buffered saline,
postfixed with 1% osmic acid and embedded in araldite. Semi-
thin resin sections were stained using toluidine blue. Ultrathin
sections were double stained with uranylacetate. Histoenzy-
mology was performed in serial transverse cryostat sections (6
µm thick), stained using routine histochemical methods [14].
Sensitive nerve biopsies were obtained from sural, peroneal
nerves or the sensory branch of the musculocutaneous nerve
(in the distal third of the leg). Nerve samples were fixed in
2.5% glutaraldehyde in 0.1 mol/l phosphate-buffered saline,
postfixed with 1% osmic acid and embedded in araldite. Semi-
thin resin transverse and longitudinal sections were stained
using haematein and eosin, solochrome blue and paraphe-
nylene diamine. Ultrathin sections were double stained with
uranylacetate and citrate. Histopathological reports and origi-
nal slides were reviewed by two medical experts who were
blinded to the electromyographic findings.
Functional outcome
Follow-up data were available in all 15 patients. The end-
points were death or time to ambulation without assistance.
The maximal duration of follow up was 12 months. Findings
were not analyzed statistically because of the relatively small
numbers included in the various groups.
Results
Clinical features
A total of 25 patients, suffering in most cases from sepsis or
SIRS following cardiac surgery, and who were undergoing
long-term mechanical ventilation (>15 days), were enrolled.
Ten patients were excluded because of previous alcoholic liver
disease or end-stage renal failure (n = 4) or a previous history
of neuromuscular disease (n = 6).
The patients' median age was 53 years (range 33–82 years),
and the median Euroscore was 7 (range 1–20). All patients
presented with at least one episode of sepsis or a systemic
inflammatory response. Multiorgan dysfunction was diag-
nosed in 10 patients, with a median Multiple Organ Dysfunc-
tion Score of 3 (range 1–4; Table 1). The most common organ
system failure was cardiovascular, and more than 86% of
patients fulfilled criteria for heart failure. Postoperative renal
dysfunction requiring continuous venovenous haemofiltration
was diagnosed in nine patients (60%). The severity of weak-
ness and variability in reflex abnormality were noted. Patients
were noted to be weak 15–40 days after ICU admission.
Because patients received neuromuscular blocking agents
and sedatives, the exact time of onset of weakness was usually
not possible to determine. Of the patients studied, 50% pre-
sented with asymmetric tetraparesia, predominantly involving
the legs. The other 50% had global tetraparesia with much
reduced muscle tone (Table 1). Five patients were areflexic,
seven had hyporeflexia and three had normal tendon reflexes.
All patients grimaced in response to painful stimuli, but sen-
sory testing was initially unreliable in most. One patient was
transiently encephalopathic.
Table 2 summarizes clinical diagnoses and medications affect-
ing the neuromuscular system in these patients with neu-
romuscular weakness syndromes. Patients in all groups
received muscle relaxants; only two were used in our unit dur-
ing the study period – vecuronium and atracurium. The groups
included patients who received large doses of muscle relax-
ants as well as patients who received none. Muscle relaxants
were used in 66% of the patients included in the study; 20%
of these received muscle relaxants for less than 24 hours. Six
patients received intravenous corticoids; four of these patients
had undergone transplants and the other two patients were
asthmatic.
Electrodiagnostic testing
The spectrum of neuromuscular causes of weakness, along
with electromyographic localization and neuromuscular biopsy
findings, is summarized in Table 2. The two most common
causes of weakness in these patients were polyneuropathy or
myopathy in isolation. Six patients presented with neuropathy,
three of whom had sensory motor neuropathy characterized by
reduced sensory and motor action potential amplitudes. Six
other patients presented with acute myopathy, characterized
by sensory and motor action potentials in the normal range or
partially reduced. Three patients presented with CIP associ-
ated with myopathy. Motor unit potentials were usually
reduced, with pathological fibrillation potentials associated.Table 1
Summary of diagnoses and medications affecting the neuromuscular system in 15 patients with neuromuscular weakness syndromes
Patient Age 
(years)
Sex Euroscore Primary disease Surgery Duration of 
MV (days)
Complications SIRS Sepsis MOD 
score
Neurological 
presentationa
Neuromuscular blocking medication Corticosteroids
Muscle relaxants Aminoglycosi
des
1 59 M 3 Coronary artery disease CABG 70 Pneumonia, kidney failure Yes Yes 2 Flaccid TP, 
stupor
Atracurium 1830 
mg, vecuronium 72 
mg
Tobramycin 
240 mg, 
gentamycin 
1120 mg
None
2 44 M 1 Obesity, asthma CABG 52 Pneumonia Yes Yes 1 Flaccid TP Atracurium 1980 
mg, vecuronium 
1640 mg
None Methylprednisolone 
240 mg
3 50 F 7 Active endocarditis VR 24 RV failure, kidney failure Yes No 2 Flaccid TP None None None
4 76 M 6 Coronary artery disease, 
hypertension
CABG 51 ARDS, septic shock Yes Yes 4 Flaccid TP None Amikacin 
3200 mg
None
5 67 M 14 Coronary artery disease CABG 40 ARDS, kidney failure Yes Yes 3 Flaccid TP Atracurium 1380 
mg
None None
6 33 M 0 Bicuspid aorta Ross procedure 25 Haemorrhagic shock, kidney 
failure, ARDS
Yes Yes 4 Flaccid TP, 
distal 
amyotrophy
Atracurium 3000 
mg
None None
7 76 F 8 Hypertension, 
endocarditis
VR 163 Septic shock, kidney failure Yes Yes 3 Flaccid TP None Gentamycin 
1000 mg
None
8 60 M 6 Coronary artery disease HT 36 Cardiac arrest, pneumonia Yes Yes 2 Flaccid TP, 
diffuse 
amyotrophy
None None Methylprednisolone 
2000 mg
9 60 M 20 Coronary artery disease HT 120 Mucormycosis, pneumonia, 
kidney failure
Yes Yes 4 Flaccid TP, 
diffuse 
amyotrophy, 
ROT
Atracurium 300 mg Gentamycin 
600 mg
Methylprednisolone 
3000 mg
10 53 M 6 Coronary artery disease HT 54 Pneumonia, kidney failure Yes Yes 4 Flaccid TP Atracurium 100 mg Tobramycin 
820 mg
Methylprednisolone 
8460 mg
11 57 M 9 Cardiomyopathy HT 28 RV failure, pneumonia, 
kidney failure
Yes Yes 3 Flaccid TP, 
ROT
None None Methylprednisolone 
3000 mg
12 26 F 6 None RV blast 64 Cardiac arrest, 
encephalopathy
Yes No 3 Flaccid TP, 
ROT
Atracurium 11,000 
mg
None None
13 77 F 10 Mitral regurgitation, 
endocarditis
VR 45 Septic shock, kidney failure Yes Yes 3 Flaccid TP Atracurium 630 mg None None
14 77 F 11 Hypertension, asthma Aortic 
dissection
34 Pneumonia, kidney failure Yes Yes 2 Flaccid TP, 
ROT
Atracurium 7300 
mg
None Methylprednisolone 
1120 mg
15 82 F 10 Hypertension Aortic 
dissection
36 Pneumonia, kidney failure Yes Yes 2 Flaccid TP, 
ROT
Atracurium 3300 
mg
None None
aNeurological presentation after stopping sedation (approximately 72 hours). CABG, coronary artery bypass grafting; HT, heart transplantation; MOD, multiple organ dysfunction; MV, mechanical ventilation; PP, 
paraparesia; TP, tetraparesia; ROT, tendon reflexes abolished; RV, right ventricular; SIRS, systemic inflammatory response syndrome; VR, valve replacement.Muscle and nerve pathology
A range of histopathological abnormalities was identified in the neuromuscular biopsies
from the 15 patients (Table 2). The most common muscle abnormality was diffuse atrophy
of fibre types I and II (14 out of 15 patients) associated with acute necrosis (12 out of 15
patients; Figs 1 and 2). There were abnormalities in the nerve biopsy from most patients
(Fig. 3; except those with acute myopathy); these included axonal degeneration and demy-
elinating lesions. In some patients (patients 5, 7 and 8), analysis of neuromuscular biopsy
revealed myopathic lesions associated with necrotic and atrophic fibres. This was associ-
ated with a huge reduction in sensory or motor action potential amplitude. Ten patients
received neuromuscular blocking agents, five of whom exhibited an acute myopathy and the
other five a peripheral neuropathy. However, two patients who did not receive any muscle
relaxant developed a neuropathic pattern (with or without myopathic lesions). All patients
who received corticosteroids exhibited a myopathic pattern (with or without axonopathic
lesions) but never an exclusively axonopathic pattern.
The overall mortality rate was 40%, with a further patient dying on the ward after ICU dis-
charge, giving a hospital mortality of 46%. Among the eight survivors at 12 months, two
patients were not ambulatory (patients 2 and 8; Table 3). Compound muscle action poten-
tials (CMAPs) were undetectable in these two patients on electrophysiological examination
(Table 2).
Table 2
Electrodiagnostic and histopathological findings in 15 patients with neuromuscular weakness syndromes
Patient Typea Electromyography Muscular biopsy Nerve biopsy
Concentric needle examinatioin Motor nerve conduction Sensory nerve conduction Atrophy Necrosis Myosin loss Axonal degeneration Demyelination
FP LP Recruitmentb
0123C V  ( m / s ) C M A P  ( m V ) C V  ( m / s ) C M A P  ( µV)
1 N + + Peroneal 46/ulnar 68 1/0.1 I/II +
2 N + + Peroneal 0/median 0 0/0 Sural 0/radial 0 0/0 II + +
3 N + + + Peroneal 33 0.1 Peroneal 41 10 I + +
4 N + + Peroneal 26/median 37 1/1 Peroneal 35/median 38 2/1 I/II + +
5 N + + + Peroneal 41 3 Peroneal 33 4 I/II + + +
6 N + + + Peroneal 40 2 Peroneal 36/radial 48 7/48 I/II + + +
7 NM + + Peroneal 0 0 Peroneal 0 0 I/II + + +
8 NM + + Peroneal 0 0 Peroneal 0 0 I/II + + +
9 NM + + + Peroneal 38 0.1 Peroneal 35/radial 48 3/8 I/II + + +
10 M + + + + Peroneal 36/median 34 0.8/0.8 Peroneal 52/radial 56 7/16 II + + No No
11 M + Peroneal 42 1.6 Peroneal 58 12 II + No No
12 M + + Peroneal 35 1.2 Peroneal 43/radial 43 20/22 I/II + No No
13 M + Peroneal 39 0.8 Peroneal 42 24 II + No No
14 M + + + + Peroneal 43 1.6 Peroneal 44 12 II + + No No
15 M + + Peroneal 40 1.0 Peroneal 42 7 II + No No
aType of neurological lesion. bRecruitment (muscular contraction): 0, absent; 1, simple; 2, weak intermediate; 4, rich intermediate. Recruitment data not available for patients 4, 8 and 12. CMAP, compound muscle 
action potential; CV, conduction velocity; FP, fibrillation potentials; LP, slow potentials of denervation; M, myopathy; N, neuropathy; NM, neuromyopathy.Critical Care    December 2004  Vol 8 No 6    Kerbaul et al.
R363
Discussion
Although acute neuromuscular weakness appears prevalent
among patients on prolonged mechanical ventilation, few
prospective studies have been reported that include both
electrophysiological and histological patterns [5,15,16]. Fur-
thermore, nerve biopsy findings are absent, even in recent pro-
spective studies [5]. Our study is among the first to perform
electromyography and obtain neuromuscular biopsies pro-
spectively for all patients included. The neurophysiological
abnormalities identified were of three types, namely CIP alone,
acute myopathy and mixed neurogenic and myogenic distur-
bances, and they developed in a group of long-term mechani-
cally ventilated patients who had undergone cardiovascular
surgery. This type of severe and disturbing complication fol-
lowing cardiac surgery has been described previously [6,17],
and led to an evaluation of hypothetical risk factors for such
neurological disorders.
It is also widely believed that the development of critical illness
neuropathy is invariably associated with multiple organ failure,
sepsis and SIRS [3,6,8,9]. Thus, CIP probably represents an
organ failure caused by sepsis and SIRS, presumably as a
result of the same basic mechanisms that lead to multiple
organ dysunction, including inflammation, thrombosis, apopto-
sis and oxidant injury [18]. In the present study, however,
peripheral neurological changes occurred in a few patients
who did not fulfill accepted objective criteria for sepsis or sin-
gle organ failure. This observation was previously reported in
four series of patients with respiratory failure [7,15,19,20]. As
might be expected, in the present study of long-term mechan-
ically ventilated patients following cardiovascular surgery, sep-
sis and multiple organ failure were common but did not seem
to be a prerequisite for the development of acute neuromuscu-
lar weakness, the cause of which remains unclear [18].
It was previously suggested that use of neuromuscular relax-
ants is associated with neuromuscular disorders in the ICU
[21-24]. Possible mechanisms include persistent effects of
these drugs or their active metabolites, pharmacological den-
ervation hastening muscle atrophy, or association of these
drugs with intravenous corticosteroids or aminoglycosides
[22,24]. Vecuronium and its steroid components were also
implicated as a cause of weakness [25]. In our study atracu-
rium was also administered in patients with prolonged neu-
romuscular weakness, although it has no steroidal component
and there is no accumulation of this molecule in the event of
Figure 1
Cryostat cross-section of a biopsy specimen from patient 10 from the  musculus vastus lateralis with acute necrotizing myopathy Cryostat cross-section of a biopsy specimen from patient 10 from the 
musculus vastus lateralis with acute necrotizing myopathy. Necrotic 
vacuolated and regenerating muscle fibres are present. Endomysial 
connective tissue is increased. Frozen section, stained with haematein 
and eosin, magnification 200×.
Figure 2
Electron microscopic changes in muscular fibres associated with a pro- nounced myosin heavy chain depletion Electron microscopic changes in muscular fibres associated with a pro-
nounced myosin heavy chain depletion. Near total loss of thick filaments 
is seen in the A band (barr = 2 µm).
Figure 3
Cross-section of a nerve biopsy specimen from patient 4 exhibiting  severe axonal neuropathy Cross-section of a nerve biopsy specimen from patient 4 exhibiting 
severe axonal neuropathy. There is loss of myelinated nerve fibres. 
Some large myelinated fibres show degenerating myelin ovoids. Sec-
ondary demyelination is seen in rare nerve fibres. Clusters of Schwann 
cells without nerve fibres are increased. Resin section, stained with par-
aphenylene diamine, magnification 115×.Available online http://ccforum.com/content/8/6/R358
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kidney or liver failure. However, we are unable to conclude that
neuromuscular relaxants predispose to the development of
neuromuscular disorders in general, or any type of neuromus-
cular disease in particular, because of the lack of a control
group. Other observational studies failed to identify neuromus-
cular relaxants as possible additional risk factors [20,31].
The link between use of aminoglycosides and CIP was previ-
ously reported [26,27]. In the present study 66% of patients
presenting with CIP received intravenous aminoglycosides,
but only five patients out of 15 received intravenous
aminoglycosides. Therefore, intravenous use of aminoglyco-
sides may be another measure of severity of sepsis and multi-
ple organ failure.
Steroid administration appears to be associated with muscular
lesions, regardless of association with neuropathy. All study
patients who received high doses of corticosteroids (cumula-
tive equivalent dose >1000 mg methylprednisolone) exhibited
a myopathic pattern (with or without associated axonopathic
lesion) but never an exclusive axonopathic pattern. This finding
supports the deleterious effect of corticosteroids predomi-
nantly on the muscles, as suggested by several studies [5,28-
32].
Electromyographic abnormalities and neuromuscular histology
patterns were concordant in 13 patients out of 15. In the two
discordant cases, electromyographic examination failed to
show any myogenic component, whereas muscle histology
suggested severe myopathy with necrotic fibres and vacuoli-
zation zones. This lack of complete agreement between neu-
rophysiological testing and muscle histology has already been
noted by Coakley and colleagues [20]. Some authors have
also indicated that it could be difficult to differentiate myopathy
from axonal motor neuropathy via electromyographic analysis
alone, especially in unconscious patients [2,5]. Thus, in the
absence of systematic muscle biopsy, some patients can be
misdiagnosed with myopathy when motor axonopathy is
present and, as shown in the present study, it is conceivable
that some patients have both myopathy and neuropathy [4].
The combination of neurophysiological testing with
neuromuscular histology could therefore help in the precise
identification of the type and severity of neuromuscular weak-
ness, and may lead to a better understanding of the causes
and consequences of neuromuscular weakness [5].
Table 3
Clinical outcome in 15 patients with neuromuscular weakness syndrome
Patient Typea ICU stay 
(days)
Clinical outcome Ambulatory activity without 
assistance in <3 months
Ambulatory activity without 
assistance in 3–12 months
Nonambulatory Mechanical 
ventilationb
1 N 86 TP, death (day 120) No No Yes No
2 N 80 Slight proximal TP, normal tendon 
reflexes
No No Yes No
3 N 25 Complete recovery with normal 
tendon reflexes
Yes Yes No No
4 N 51 TP with marked atrophies, death (day 
51)
No No Yes Yes
5 N 44 Complete recovery of legs, distal 
spasticity of arms
Yes Yes No No
6 N 45 Slight proximal TP Yes Yes No No
7 NM 281 TP with marked atrophies, death (day 
281)
No No Yes Yes
8 NM 76 TP with marked atrophies No No Yes No
9 NM 105 TP with marked atrophies, death (day 
105)
No No Yes Yes
10 M 204 TP with marked atrophies, death (day 
204)
No No Yes Yes
11 M 57 Slight left upper MP Yes Yes No No
12 M 91 Slight proximal TP No Yes No No
13 M 45 TP with marked atrophies, death (day 
45)
No No Yes Yes
14 M 56 Complete recovery with normal 
tendon reflexes
Yes Yes No No
15 M 36 TP with marked atrophies, death (day 
36)
No No Yes No
aType of neurological lesion. bWeaning from mechanical ventilation at the end of the intensive care unit (ICU) stay. M, myopathy; MP, 
monoparesia; N, neuropathy; NM, neuromyopathy; TP, tetraparesia.Critical Care    December 2004  Vol 8 No 6    Kerbaul et al.
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There was a high mortality rate in patients with acute neu-
romuscular weakness. Patients who died did so as a result of
their underlying diseases and not from neuromuscular affec-
tion. These findings are similar to those from previous studies
that reported on neuromuscular abnormalities [4,33]. In fact,
the mortality rate and functional prognosis were similar
between survivors with acute myopathy and those with neu-
ropathy. However, of the three patients with combined neuro-
logical and muscular lesions, two died and the third survived
but with severe functional disability.
Survivors from critical illness have sustained impairments in
physical function and health status, even after 1 year of recov-
ery [34-36]. In our study, of the eight survivors at 12 months
only two were not ambulatory (patients 2 and 8). These were
the only two survivors in whom CMAPs were undetectable on
electrophysiological examination. This electrophysiological
finding attests to the severity of the axonopathy and may be a
predictor of prolonged functional disability. However, because
of the relatively small number of patients in this group, addi-
tional studies are necessary to confirm this clinical finding.
Certain limitations of present study are worthy of mention. This
prospective study evaluated electrophysiological and histolog-
ical neuromuscular patterns in 15 ICU patients with prolonged
mechanical ventilation after a complicated course following
cardiovascular surgery. However, because the lack of control
group and the small numbers of patients included, we were
not able to determine precisely the risk factors for each pathol-
ogy. Furthermore, as in previous studies [20,37], we were una-
ble to determine exactly the time of onset of weakness.
Therefore, electrophysiological and histological analyses were
not performed at the same time point for all patients.
Conclusion
Neurophysiological and neuromuscular histological abnormal-
ities associated with acute neuromuscular weakness were
identified in mechanically ventilated patients in the ICU who
had undergone cardiovascular surgery. Such patients are
assumed to present with reversible neurological damage,
although in a proportion this damage could be irreversible.
Among survivors the absence of CMAPs on electrophysiolog-
ical examination could suggest prolonged functional disability.
Because of the lack of sensitivity of clinical examination in such
patients, combined electromyographic diagnosis and neu-
romuscular abnormalities on histology could help to identify
the type and severity of neuromuscular weakness, and the
functional prognosis.
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